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Abstract
Background: The authors sought to monitor the impact of widespread varicella vaccination on
the epidemiology of varicella and herpes zoster. While varicella incidence would be expected to
decrease, mathematical models predict an initial increase in herpes zoster incidence if re-exposure
to varicella protects against reactivation of the varicella zoster virus.
Methods: In 1998–2003, as varicella vaccine uptake increased, incidence of varicella and herpes
zoster in Massachusetts was monitored using the random-digit-dial Behavioral Risk Factor
Surveillance System.
Results: Between 1998 and 2003, varicella incidence declined from 16.5/1,000 to 3.5/1,000 (79%)
overall with ≥ 66% decreases for all age groups except adults (27% decrease). Age-standardized
estimates of overall herpes zoster occurrence increased from 2.77/1,000 to 5.25/1,000 (90%) in the
period 1999–2003, and the trend in both crude and adjusted rates was highly significant (p < 0.001).
Annual age-specific rates were somewhat unstable, but all increased, and the trend was significant
for the 25–44 year and 65+ year age groups.
Conclusion:  As varicella vaccine coverage in children increased, the incidence of varicella
decreased and the occurrence of herpes zoster increased. If the observed increase in herpes zoster
incidence is real, widespread vaccination of children is only one of several possible explanations.
Further studies are needed to understand secular trends in herpes zoster before and after use of
varicella vaccine in the United States and other countries.
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Background
Prior to the licensure of varicella vaccine in the U.S. in
1995, varicella (chickenpox) was a highly prevalent dis-
ease of childhood, resulting in approximately four million
cases and an average of 10,630–13,500 hospitalizations
and 90 deaths in the U.S. each year [1-4]. After primary
infection, the varicella zoster virus (VZV) lies dormant in
sensory ganglia and can reactivate later, producing herpes
zoster (shingles) and sometimes persistent, debilitating
pain and other serious complications [5]. Associated with
a decline in specific cell-mediated immunity, herpes
zoster affects some 600,000–900,000 mostly elderly or
immunocompromised people in the U.S. each year, its
incidence increasing with age [1,6].
Establishing and/or enhancing varicella and herpes zoster
surveillance has been essential in order to assess the
impact of widespread varicella vaccination [7,8]. Despite
the fact that national vaccination coverage among chil-
dren 19–35 months of age had risen to 85 percent by
2003 [9], varicella did not become a nationally notifiable
disease in the U.S. until that year. Herpes zoster has never
been a nationally notifiable disease, and no states require
reporting of cases. Studies of herpes zoster using different
methods have reported unadjusted incidence rates rang-
ing from 1.3 to 4.8 per 1,000 population [10-13], but
there is little documentation of secular trends over time.
Some studies suggest that re-exposure to VZV after pri-
mary infection may decrease the risk of herpes zoster
through immunologic boosting [14-16]. If this is the case,
widespread use of varicella vaccine could, by reducing cir-
culating VZV, increase the incidence of herpes zoster over
the first few decades of universal childhood vaccination.
On the other hand, studies in leukemic as well as healthy
children have found a lower incidence and severity of her-
pes zoster among vaccinated than among comparable
unvaccinated children [17-21], which would appear to
bode well for the more distant future if vaccine coverage
reaches high levels. Clearly, consistent and long-term sur-
veillance for herpes zoster will be necessary in order to
fully assess the impact of varicella vaccination on the epi-
demiology of zoster.
Starting in 1998, as uptake of varicella vaccine was
increasing (due in part to immunization requirements for
daycare and school entry), the Massachusetts Department
of Public Health, in collaboration with the Centers for
Disease Control and Prevention (CDC), enhanced vari-
cella and herpes zoster surveillance by including ques-
tions in the Behavioral Risk Factor Surveillance System
(BRFSS) about the occurrence of these diseases. Research-
ers in Kentucky had used both the BRFSS and a school-
based cohort study to estimate age-specific varicella inci-
dence in 1990–1992 and found generally close concord-
ance between results of the two methods [22].
Herein, we analyze varicella and herpes zoster incidence
as estimated by the Massachusetts BRFSS in the period
1998–2003.
Methods
Vaccine use and coverage
The Massachusetts Department of Public Health began to
distribute varicella vaccine in September 1996 for use in
12–18-month-olds and susceptible sixth-graders. In Octo-
ber 1997, eligibility was expanded to include all children
between 1 and 18 years of age. Beginning in August 1998,
proof of immunity to varicella (written documentation of
age-appropriate immunization or physician-certified reli-
able history of disease) was required for child-care center
attendance for children ≥  19 months of age who were
born after 1996. Finally, in September 1999, proof of
immunity became required for entry into kindergarten
and seventh grade.
Vaccine coverage estimates were obtained from the
National Immunization Survey. The CDC conducts this
random-digit-dial telephone survey of households regard-
ing the immunization status of children 19–35 months of
age each year. National Immunization Survey methods
have been published elsewhere [23].
Varicella and herpes zoster incidence
The BRFSS is an ongoing, random-digit-dial telephone
survey of adults aged 18 years and older and gathers infor-
mation on health characteristics, risks, and preventive
behaviors. The survey is conducted in all U.S. states in col-
laboration with the CDC and state health departments.
Once a household is contacted, one adult is randomly
selected for interview. Characteristics of the BRFSS are
described in more detail elsewhere [24].
The BRFSS includes a core set of questions asked by all
states, as well as optional topics added by individual
states. Massachusetts added questions about chickenpox
and shingles among all household members in 1998–
2000 and 2002–2003. Respondents were first asked to
enumerate all household members and their ages. Trained
interviewers then asked respondents whether any house-
hold members had chickenpox in the past 12 months and
the current age(s) of the affected household member(s).
Respondents were also asked whether any household
members had ever  had shingles, the current age(s) of
affected household member(s), and the age(s) when they
had shingles.
For these analyses, we calculated the annual age-specific
incidence of varicella and herpes zoster per 1,000 popula-
tion. In 1998 only, the response to the age-at-shingles
question was recorded only in five-year age groups (0–4
years, 5–9 years, etc.), so annual incidence of herpesBMC Public Health 2005, 5:68 http://www.biomedcentral.com/1471-2458/5/68
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zoster could not be calculated for that year. We made
some simplifying assumptions in estimating age-specific
annual incidence of varicella and herpes zoster. For vari-
cella, each case that was reported as occurring in the pre-
vious 12 months was assigned to the individual's current
age. For herpes zoster, a case was counted as occurring
within the previous year if the age at the time of the
reported case was the same as or 1 year less than the cur-
rent age. Our data on herpes zoster combine incident and
recurrent cases, as no distinction was made between these
in the interview. In presenting the varicella data, we used
five standard child/adolescent age groups and grouped
adults 20 years and older into a sixth. In the case of herpes
zoster, we used four 20–25-year age intervals in order to
increase the stability of the data.
BRFSS data were weighted to account for probability of
selection and differential participation by age, sex, and
race/ethnicity. All data were analyzed using appropriate
procedures in SAS and SUDAAN, taking into account the
survey sampling scheme, intra-class correlation among
household members, and weighting of the data (SAS
Institute, Cary, NC; SUDAAN, RTI, Research Triangle Park,
NC). Tests for linear trend were done using logistic regres-
sion (with incidence as the outcome and year as the expo-
sure variable), adjusting for age in comparisons of overall
incidence. Age standardization was based on the standard
2000 U.S. population [25] in 14 mostly five-year age
groups: 1–14, 15–19, 20–24, 25–29, 30–34, 35–39, 40–
44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74, and 75+.
The oldest group was not further subdivided due to
diminishing cell sizes.
Results
Response rate
The response rate for the Massachusetts BRFSS as a whole
was 59% in 1998, 55% in 1999, 41% in 2000, 66% in
2002, and 65% in 2003. The large apparent increase in
response rate in 2002 was mainly due to the fact that in
that year BRFSS expanded the number of case disposition
codes in order to more accurately differentiate between
different types of response and non-response and to bring
the BRFSS disposition codes more in line with those rec-
ommended by the American Association for Public Opin-
ion Research (AAPOR). This broader array of codes allows
for more accurate accounting of participation rates, such
as response rates (pers. comm., Dr. Michael Link, BRFSS,
CDC). The number of households responding to the vari-
cella-herpes zoster module ranged between 4,200 and
4,900, representing between 11,000 and 14,000
members.
Vaccine coverage
Using National Immunization Survey estimates for Mas-
sachusetts children 19–35 months of age [26], coverage
increased from 23 percent in 1997 to 48 percent in 1998
and reached 89 percent in 2003 (Figure 1).
Varicella incidence
In 1998, the highest incidences of varicella were observed
in children 1–4 years of age (83 per 1,000) and 5–9 years
of age (76 per 1,000). Between 1998 and 2003, overall
unadjusted varicella incidence declined by 13.0 cases per
1,000 (79%), from 16.5 to 3.5 per 1,000 (p < 0.0001;
Table 1 and Figure 1). The overall incidence of varicella
was higher in 2003 than in 2002 but not statistically sig-
nificantly so. Over 1998–2003, incidence declined for all
age groups, with the greatest decreases among infants, 1–
4-, 5–9-, and 15–19-year olds (100%, 89%, 80%, and
92%, respectively) and the smallest among adults (27%).
The trends were highly significant (p < 0.0001) for the 1–
4- and 5–9-year olds and significant (p = 0.02) for the 10–
14-year olds.
Herpes zoster incidence
Overall age-standardized (and crude) incidence per 1,000
of herpes zoster was 2.77 (2.23) in 1999, 3.54 (3.57) in
2000, 6.47 (6.51) in 2002, and 5.25 (5.38) in 2003 (Table
2), and the increasing trend was highly significant for
both the age-adjusted (p < 0.0009) and crude (p <
0.0001) incidences. The increase in the age-standardized
incidence was 90 percent over the five-year period. Over
this period, age-specific incidences increased by 41–161
percent, although the annual age-specific incidence esti-
mates were somewhat unstable (Table 2, Figure 2).
Discussion
The age-specific incidences of varicella in 1998 were gen-
erally within the range of estimates reported in studies
conducted using a variety of methods in other parts of the
U.S. prior to the introduction of the vaccine [1,22,27-29].
We noted a marked reduction in varicella incidence in all
age groups in Massachusetts over the period 1998–2003;
the decline was between 66 and 100 percent for all groups
except adults, in whom incidence decreased by 27 per-
cent. Vaccine coverage in Massachusetts 19–35-month-
olds increased from 48 to 89 percent over the same 6-year
period.
Seward et al. [30] observed a similarly consistent decline
over the 6-year period of 1995–2000 in three areas of
active surveillance, whose range of vaccine coverage as
measured by the National Immunization Survey encom-
passed Massachusetts' coverage each year. Likewise,
Jumaan et al. [31] documented a decline in age-adjusted
incidence of varicella from 2.63 per 1,000 in 1995 to 0.92
per 1,000 in 2002. Decreases in varicella incidence after
vaccine licensure have been noted in Illinois, Michigan,
Texas, and West Virginia as well [32]. Similarly, large
decreases in incidence among children in childcareBMC Public Health 2005, 5:68 http://www.biomedcentral.com/1471-2458/5/68
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centers and among U.S. Navy recruits have been associ-
ated with varicella vaccination [33,34].
The overall incidence of varicella was higher in 2003 than
in 2002, although the difference was not statistically sig-
nificant. No such upturn was apparent in Massachusetts
Department of Public Health surveillance data, which
showed an overall decrease of 20 percent in cases and inci-
dence between 2002 and 2003, in spite of increased
efforts to stimulate varicella reporting. (Overall incidence
of herpes zoster decreased from about 6 to about 5 per
1,000 from 2002 to 2003, but the change was not statisti-
cally significant for either the crude or the age-standard-
ized estimates.)
Age-standardized overall annual herpes zoster incidence
increased by 2.5 cases per 1,000 (90%) over the 1999–
2003 period, to 5.25 per 1,000, higher than the age-stand-
ardized estimates derived using the same standard popu-
lation from a study in the Netherlands in 1994–1999
(3.34 per 1,000) [35] and from a study in Seattle, Wash-
ington in 1992–2002 (range: 3.47–4.05 per 1,000) [31]
but not substantially higher than the estimate obtained
from a study in France in 1997–1998 (4.55 per 1,000)
[13]. The age-specific incidences of herpes zoster found
here were consistently higher than in a Minnesota study of
50 years ago [12], and more than half of the age-specific
point estimates in four other studies [11-13,6] fell below
the 95 percent confidence intervals of our combined
2002–2003 estimates. (Confidence intervals for most of
these previous studies were not available for comparison.)
The four age groups showed increases of 41–161 percent,
and the trend was significant for the 25–44 and 65+ age
groups. In spite of the fact that the annual age-specific esti-
mates of herpes zoster incidence were unstable, as can be
seen particularly in the 65+ year-old age group (Figure 2),
it does appear that there was a generally increasing trend
in herpes zoster incidence for all age groups, based on
these four years of data over a five-year period. This trend
appears to conflict with findings from the Seattle study, a
large longitudinal study in a health-maintenance organi-
zation in which age-adjusted as well as age-specific herpes
zoster incidences remained relatively stable over the
Varicella immunization levels and proportion of Massachusetts youth with varicella, 1998–2003 Figure 1
Varicella immunization levels and proportion of Massachusetts youth with varicella, 1998–2003. Annual National Immunization 
Survey estimates of varicella immunization levels and percent of Massachusetts residents < 20 years of age with varicella in the 
past year by date of interview, 1998–2003.
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period 1992–2002, during the latter four years of which
varicella incidence declined [31].
If in fact herpes zoster incidence is rising in the current
period, there are several possible explanations, which may
be operating in combination. One of these is varicella vac-
cination. Widespread varicella vaccination may end up
increasing herpes zoster incidence among adults who
have had varicella. Recent studies have suggested a protec-
tive effect against herpes zoster from exposure to varicella
and/or children [14-16]. One mathematical model pre-
dicts a long-term (equilibrium state) elevated incidence of
herpes zoster of 20 percent or more relative to pre-vacci-
nation levels, under the assumption of immunologic
boosting by exposure to VZV, if vaccine virus has a 75 per-
cent or greater chance of reactivating to cause herpes
zoster [36]. A later model by Brisson et al. [16], which was
parameterized by means of a large, population-based sur-
vey and assumes that immunity from boosting lasts for 20
years, predicts a substantial increase in herpes zoster cases
over the first 30–50 years after the initiation of mass vac-
cination, peaking about 20 years after the start of mass
vaccination at an incidence of 51 percent over the pre-vac-
cination level and eventually falling below the initial
incidence. Those aged 10–44 years at the start of mass vac-
cination will be most affected, according to the model,
their lifetime risk exceeding 50 percent, compared to 33
percent in the pre-vaccination period – most will have
been previously infected but will no longer experience
boosting by exposure to children with varicella disease.
Table 1: Age-specific incidence (cases per thousand) of varicella and trends, Massachusetts, 1998–2003
Year Parameter Age group in years
< 1 1–4 5–9 10–14 15–19 20+ All ages, crude
1998
na 144 762 1025 922 791 8241 11885
Cases 4 66 83 23 9 34 219
Incidence 15.2 82.6 76.4 18.6 30.2 2.2 16.5
95% CI 4.7–49.5 59.9–113.9 55.0–104.5 10.8–32.0 8.3–109.4 1.4–3.5 12.8–21.3
1999
na 318 1603 1131 1094 898 8483 13527
Cases 4 46 41 11 3 17 122
Incidence 6.2 36.5 38.2 10.4 2.9 1.7 10.9
95% CI 1.2–31.6 21.1–63.0 24.8–59.0 4.8–22.5 0.6–13.4 0.9–3.4 7.8–15.1
2000
na 139 671 790 918 693 7518 10729
Cases 1 7 9 9 3 3 32
Incidence 11.4 11.6 10.3 8.8 4.2 0.3 2.7
95% CI 1.4–53.7 4.7–25.6 4.8–20.6 4.0–18.1 0.8–19.8 0.1–1.23 1.8–4.3
2002
na 161 600 780 831 705 7789 10866
Cases 1 4 5 3 1 6 20
Incidence 8.7 4.3 8.0 4.6 1.4 0.5 1.7
95% CI 1.1–44.6 1.2–13.9 3.0–20.0 1.3–15.4 0.2–9.7 0.2–1.1 1.0–2.8
2003
na 155 613 827 914 726 8012 11247
Cases 0 7 15 6 2 10 40
Incidence 0.0 8.8 15.0 6.4 2.3 1.6 3.5
95% CI 3.6–20.2 7.8–27.0 2.7–14.4 0.6–9.2 0.8–3.1 2.3–5.2
1998–2003
% change for period -100% -89% -80% -66% -92% -27% -79%
p for trend test n.a. <0.0001 <0.0001 0.02 0.15 0.16 <0.0001
a N's exclude individuals for whom age or varicella status was missing. The number excluded for these reasons was 494, 233, 478, and 195 in 1999, 
2000, 2002, and 2003, respectively. Values for n's and numbers of cases are unweighted, whereas incidence rates and 95% confidence intervals are 
based on weighted analysis.BMC Public Health 2005, 5:68 http://www.biomedcentral.com/1471-2458/5/68
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The Brisson model predicts the greatest rates of increase in
herpes zoster incidence in the years just after the start of
mass varicella vaccination, with a 40 percent increase over
the pre-vaccination level expected by Year 10. Yet, over
just a five-year period, we saw an increase of this magni-
tude in the 45–64-year age group and even larger increases
in the other age groups, and it seems unlikely that vari-
cella vaccination alone can explain our herpes zoster
results. Other possible explanations include increases in
the proportion of people with immunosuppressive condi-
tions and therapies, in the duration of those conditions
and treatments, and/or in the prevalence of other trigger-
ing factors. Some past studies have noted an increase in
zoster incidence well before the availability of varicella
vaccine, one finding 28- and 41-percent increases for Min-
nesota women and men, respectively, between the late
1940s and the late 1950s [12] and one finding a 35-per-
cent increase between 1979 and 1997 in Canada [37].
Similarly, data from the National Health Interview Survey
suggest that incidence of herpes zoster rose in the 60+ age
groups between 1974 and 1994 [38].
Our study is subject to several limitations. Our method of
estimating annual incidence of herpes zoster, by which a
case was counted as occurring within the past year if the
age at the time of the reported case was the same as or 1
year less than the age at interview, would tend to overesti-
mate annual incidence because this encompasses a period
greater than 12 months. The inclusion of recurrent cases
with first-time cases would have the same effect. However,
any overestimation due to these factors would be felt uni-
formly over age groups and time and would not be
expected to influence year-to-year differences. Neverthe-
less, this would affect comparisons with other studies and
likely contributes to our generally higher rates.
Secondly, varicella and herpes zoster incidences were
based on respondent recall, both self- and proxy-report,
Table 2: Age-specific incidence (cases per thousand) of herpes zoster and trends, Massachusetts, 1999–2003
Year Parameter Age group in years
1–24 25–44 45–64 65+ All ages, crude All ages, standardized a
1999
nb 5655 4230 2214 911 13010
Cases 5 14 11 10 40
Incidence 0.87 1.87 4.82 6.9 2.23 2.77
95% CI 0.25–3.05 0.90–3.88 2.36–9.86 2.97–16.05 1.46–3.43 1.82–4.20
2000
nb 3668 3449 2211 1121 10449
Cases 2 12 13 8 35
Incidence 0.46 3.74 6.45 6.45 3.57 3.54
95% CI 0.11–1.91 2.04–6.76 3.60–11.29 3.04–13.16 2.50–5.08 2.48–5.03
2002
nb 3469 3234 2451 1303 10457
Cases 6 14 20 23 63
Incidence 1.70 5.13 7.42 20.03 6.51 6.47
95% CI 0.71–4.03 2.65–9.70 4.39–12.28 12.46–30.59 4.86–8.67 4.92–8.47
2003
nb 3698 3260 2700 1278 10936
Cases 8 16 18 14 56
Incidence 2.19 4.88 6.79 11.74 5.38 5.25
95% CI 1.05–4.50 2.86–8.20 4.02–11.23 6.57–20.12 4.03–7.14 3.96–6.94
1999–2003
% change for period 152% 161% 41% 70% 141% 90%
p for trend test 0.10 0.03 0.42 0.03 0.0001 0.0009
a Incidence is standardized using the standard 2000 U.S. population. The p-value is from age-adjusted analysis for trend using logistic regression.
b N's exclude individuals for whom age or herpes zoster status was missing. The number excluded for these reasons was 1011, 513, 887, and 506 in 
1999, 2000, 2002, and 2003, respectively. Values for n's and numbers of cases are unweighted, whereas incidence rates and 95% confidence 
intervals are based on weighted analysis.BMC Public Health 2005, 5:68 http://www.biomedcentral.com/1471-2458/5/68
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and we did not validate the accuracy of the reporting.
Proxy reporting may or may not introduce reporting error,
depending on the health condition in question and the
relationship of the respondent to the person about whom
information is sought [39,40]. Regarding varicella, in our
combined data for 1999 and 2000, a parent or step-parent
was the respondent in more than 90 percent of house-
holds with children, and restricting the varicella analysis
to these parent-respondents did not appreciably change
our estimates of annual age-specific incidence. Research-
ers using a telephone survey to investigate varicella inci-
dence in a city in Minnesota estimated through medical
chart abstraction that 13 percent of parental reports of
varicella in the previous year were either not varicella or
occurred more than 13 months before the interview [28].
Our data could reflect similar over-reporting; however,
error of this nature would not likely change from year to
year and thus the trends would not be affected. One study
found shingles self-report among the elderly to be accu-
rate, with few false-positive and false-negative reports
when compared to physician diagnosis [41]. We found no
significant difference between shingles incidence in
respondents of age 50 and older and shingles incidence in
the same age group as reported by proxies.
Also, in this study, herpes zoster was not likely often diag-
nosed by laboratory testing. If the public or physicians
became more aware of zoster in the latter years of the
study, there might have been more of a tendency to
attribute rash illness to zoster with each successive annual
survey, leading to an increase in observed incidence. How-
ever, we noted no increasing attention to zoster in the
popular media nor a concern among physicians about a
projected increase in incidence. Thus, we doubt that the
observed trend is due to greater awareness.
We did not collect data on underlying immunosuppres-
sive conditions, which would have permitted us to exam-
ine the extent to which changes in herpes zoster incidence
were related to changes in the prevalence of such diseases
or therapies. Although it is unlikely this prevalence
changed much in the five-year study period, it is conceiv-
able that the proportion of respondents with such condi-
tions varied randomly from year to year, which could have
affected the results.
Finally, the response rate for the BRFSS has been uneven,
hitting a low of 41 percent in 2000. If the incidence of
varicella or herpes zoster differs among responders and
non-responders, this could introduce some bias in the
estimates of both the absolute incidence and of trends
Annual incidence of herpes zoster by age, 1999–2003 Figure 2
Annual incidence of herpes zoster by age, 1999–2003. Annual incidence of herpes zoster by age: comparison of Harvard Com-
munity Health Plan (HCHP), 1990–1992 [6], and the Massachusetts Behavioral Risk Factor Surveillance System (BRFSS), 1999, 
2000, 2002, and 2003.
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over time. However, a comparison of the 2000 BRFSS
sample to the 2000 U.S. Census data for Massachusetts
concluded that the BRFSS sample reflected its target pop-
ulation in most demographic and socioeconomic varia-
bles despite its low response rate [42]. Any differences in
characteristics that might be relevant to herpes zoster inci-
dence, such as race/ethnicity and proportion of house-
holds with children, were slight. The proportion of
households with children in the sample varied little
between 2000 and 2003, from a low of 37.1 percent to a
high of 38.2 percent. In 1999, it was 33.7 percent, but
given that the effect of living with children is thought to
be protective, this difference would not explain our
results.
Conclusion
As varicella vaccine coverage in children increased, the
incidence of varicella decreased and the occurrence of her-
pes zoster increased. If the observed increase is real, wide-
spread vaccination of children is only one of several
possible explanations.
Further research on herpes zoster is clearly warranted, par-
ticularly as a vaccine to prevent herpes zoster and its com-
plications is likely to be available in the United States
within the next few years [43-45]. A better understanding
is needed of risk factors, the possible roles of internal
(from subclinical reactivation) and external (from expo-
sure to circulating VZV) boosting in preventing or delay-
ing zoster, and temporal trends in incidence since mid-
century. Additional methods for surveillance for herpes
zoster should be considered to monitor the impact of
widespread varicella vaccination of children as well as the
impact of VZV vaccination of adults, should it become
generally recommended.
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